AURORA Study-A Transformative Approach to Support PrEP Medication Persistence

Description

This study is designed to test the hypothesis that, compared to oral PrEP, use of CAB-LA in underserved populations in a real-world setting supported by a digital health companion program will be associated with greater medication adherence, persistence, retention-in-care, and improved PROs. Patients in the study will receive current standard care for HIV prevention and be offered enrollment in the digital health companion program. Goal of the study is to evaluate medication adherence and persistence in patients receiving CAB-LA vs oral PrEP and who engage with a digital health companion program.

Conditions

HIV Infections

Study Overview

Study Details

Study overview

This study is designed to test the hypothesis that, compared to oral PrEP, use of CAB-LA in underserved populations in a real-world setting supported by a digital health companion program will be associated with greater medication adherence, persistence, retention-in-care, and improved PROs. Patients in the study will receive current standard care for HIV prevention and be offered enrollment in the digital health companion program. Goal of the study is to evaluate medication adherence and persistence in patients receiving CAB-LA vs oral PrEP and who engage with a digital health companion program.

AURORA Study-A Transformative Approach Utilizing Behavioral Economics, Education, and Data Science to Support Patients Initiating PrEP With Retention-in-care and Medication Persistence

AURORA Study-A Transformative Approach to Support PrEP Medication Persistence

Condition
HIV Infections
Intervention / Treatment

-

Contacts and Locations

Charleston

West Virginia Health Right, Charleston, West Virginia, United States, 25311

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Initiation of or current user of PrEP with CAB-LA, daily FTC/TDF, or daily FTC/TAF prescribed in accordance with the WVHR standard of care practices (based practices on CDC PrEP 2021 Clinical Practice Guidelines) by a licensed HCP
  • * PrEP dispensed by WVHR pharmacy
  • * Access to a smart phone
  • * Receiving HIV PrEP care outside of WVHR
  • * Positive HIV diagnosis
  • * Contraindication to oral or injectable PrEP therapy
  • * Receiving oral bridging therapy prior to injectable PrEP therapy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

WV Health Right, Inc.,

Study Record Dates

2025-06-30